Nuclear medicine in urological cancers: What is new? - Abstract

The diffusion of PET/computed tomography has opened up a new role for nuclear imaging in urological oncology.

Prostate cancer is evaluated with choline (11C or 18F) PET due to a lack of sensitivity of 18F-fluorodeoxyglucose (FDG). However, many new tracers, such as 18F-fluorocyclobutane-1-carboxylic acid and (68)Ga-prostate-specific membrane antigen, are under investigation, offering promising results in the particular setting of radically treated patients with biochemical relapse. The performance of 18F-FDG depends on the histological type; indeed, renal cell cancer may present variable metabolic uptake. In this field, mainly antibodies labeled with positron emitters are under clinical evaluation. Finally, 18F-FDG PET/computed tomography has been proven to show good accuracy in detecting metastatic testicular and bladder cancers, despite not having valid results in detecting local disease. The urological cancer diagnostic process is currently under continuous development.

Written by:
Nanni C, Zanoni L, Fanti S.   Are you the author?
OU Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna Policlinico S Orsola-Malpighi, Via Massarenti, 9-40138 Bologna, Italy.

Reference: Future Oncol. 2014 Oct;10(13):2061-72.
doi: 10.2217/fon.14.87


PubMed Abstract
PMID: 25396777

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe